This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Seer files ITC complaint against Nanomics
Business patent infringement lawsuit

Seer files ITC complaint against Nanomics

Analysis based on 6 articles · First reported May 29, 2026 · Last updated May 29, 2026

Sentiment
20
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market impact is positive for Seer, Inc. as it actively defends its intellectual property, potentially strengthening its competitive position and investor confidence. Conversely, Nanomics Biotechnology Company faces negative market sentiment due to the legal challenges and potential exclusion of its products from the United States market.

Biotechnology Medical Devices
Event Summary

Seer, Inc. has filed a complaint with the United States — United States International Trade Commission (ITC) against Nanomics Biotechnology Company for patent infringement related to nanoparticle protein enrichment technology. This ITC complaint follows a federal district court patent infringement suit filed on May 12, 2026. Brigham and Women s Hospital has also joined the ITC complaint. Seer, Inc. seeks an investigation into Nanomics Biotechnology Company's importation and sale of its Proteonano kits and workstations, and an exclusion order to bar these products from entering the United States. Omid Farokhzad, CEO of Seer, Inc., stated that these actions are crucial to protect the company's technology, innovations, and product integrity.

Entities Involved
stock
Seer, Inc.
Seer, Inc. filed a complaint against Nanomics Biotechnology Company for patent infringement, seeking to protect its intellectual property in nanoparticle protein enrichment. This action aims to safeguard its market position and technology.
Importance 100.0 Sentiment 30.0
priv
Nanomics Biotechnology Company
Nanomics Biotechnology Company is accused of infringing on Seer, Inc.'s patents related to nanoparticle protein enrichment, leading to a complaint filed at the United States — United States International Trade Commission and a federal district court suit. This could result in an exclusion order barring its products from entering the United States.
Importance 90.0 Sentiment -50.0
govactor
United States — United States International Trade Commission
The United States — United States International Trade Commission is the body where Seer, Inc. filed its complaint against Nanomics Biotechnology Company, and will investigate the alleged patent infringement and potentially issue an exclusion order.
Importance 70.0 Sentiment 0.0
per
Omid Farokhzad
Omid Farokhzad, Chair and CEO of Seer, Inc., emphasized the company's commitment to protecting its technology and innovations through legal action.
Importance 40.0 Sentiment 0.0
cnt
United States
The United States is the jurisdiction where the patent infringement complaints were filed and where an exclusion order could bar products from entering.
Importance 10.0 Sentiment 0.0
Relationships
Seer, Inc. related ↔ Omid Farokhzad
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.